Needham & Company Reiterates a 'Buy' on Æterna Zentaris (AEZS); Busy Summer Brings Completion of Perifosine and AEZS-108 Pivotal Trials

Article Stock Quotes (1) Comments (0)

Needham & Company reiterates a 'Buy' on Æterna Zentaris (NASDAQ: AEZS) price target of $5.00.

Needham analyst says, "Recently, Aeterna Zentaris reviewed financial results and company progress in 2Q11 as well as expected events for the next 6-12 months. The pivotal X-PECT trial of perifosine in colorectal cancer (CRC) has completed enrollment, with data expected by YE11/early 2012. The pivotal trial of AEZS-130 as the first oral diagnostic test for Adult Growth Hormone Deficiency (AGHD) also completed enrollment, with data expected late August and a potential NDA submission in early 2012. In addition, the Company plans to initiate a pivotal trial of AEZS-108 in endometrial cancer. Also, the Company is harnessing its proprietary development platform for advancement of its earlier stage pipeline."

For more ratings news on Æterna Zentaris click here and for the rating history of Æterna Zentaris click here.

Shares of Æterna Zentaris closed at $1.64 yesterday, with a 52 week range of $0.93-$2.68.

---

Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW

---

*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here

---

---

You May Also Be Interested In

• Wedbush Downgrades salesforce.com (CRM) to Neutral
• Dollar Tree (DLTR) Beats But Looks Stretched - Jefferies
• Needham & Company Boosts Numbers on Infoblox (BLOX) on Strong Q3

Create E-mail Alert Related Categories

Analyst Comments

Related Entities

Needham & Company, Earnings

Add Your Comment

Name

Subject

Body

Share on Facebook

Verification
can't see the text?
click here to refresh the image.
what's this?